Effects of Levosimendan on Hemodynamics and Prognosis in Patients with Sepsis: A Meta-Analysis and Systematic Review

Guofeng Yu, Dongliang Meng, Xiaolong Xi and Fengqin Li

Sepsis represents a critical issue that arises when the body’s immune system excessively reacts to an infection, resulting in harm to organs and tissues. Comprehending host-microorganism interactions is essential for formulating novel therapies and evaluating disease advancement. Therefore, this meta-analysis was intended to examine the impact of levosimendan on mortality and haemodynamics in sepsis patients. This meta-analysis examined Embase, PubMed, Cochrane Library, Web of Science, China National Knowledge Network (NKI) and Wanfang Database Data, Chinese Biomedical Literature Database (CBM) and VIP Database for levosimendan, sepsis and septic shock. This research examined publicly accessible clinically randomised controlled trials of levosimendan in sepsis patients, measuring left ventricular ejection fraction, work index, cardiac index and lactate level-all data integration, publication bias detection and sensitivity analysis were carried out. In this meta-analysis, 15 studies were involved. According to the findings, there was no statistically significant variance (p>0.05) in the 28-day death rate between the levosimendan-treated sepsis patients and the control category. Levosimendan, however, can lower the left ventricular function index, raise the left ventricular ejection fraction, enhance the cardiac index and successfully lower lactate levels in sepsis patients.However, the drug has shown positive effects in improving hemodynamic parameters and therefore, more clinical trials are necessary to verify the value of levosimendan in managing hemodynamic problems associated with sepsis.

View Fulltext Back